Home / Cancer and immune system / Lorlatinib
ATC L01ED05 · Anaplastic Lymphoma Kinase (ALK) Inhibitors · updated 2 Nov 2026
Lorlatinib shortage
As of 2 Nov 2026, Lorlatinib has a reported shortage in 1 of the 16 countries we track (United States), covering 1 product from 1 company.
Is there a Lorlatinib shortage?
Yes. As of 2 Nov 2026, Lorlatinib is reported short in 1 of the 16 countries we track: United States. No company has given a return date.
Timeline
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Pfizer PFE · NYSE
Affected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) discontinuation | Pfizer Inc. | 15 Jun 2026 | not given | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.
Questions
Is there a Lorlatinib shortage?
Yes. As of 2 Nov 2026, Lorlatinib is reported short in 1 of the 16 countries we track: United States. No company has given a return date.
When will Lorlatinib be back in stock?
No return date has been given; United States: no date given. These are company estimates reported to each authority.
Why is Lorlatinib in short supply?
The most common reason reported is: not stated. Reasons by product are listed in the table below.
Which companies have Lorlatinib shortages?
Pfizer.